0001193125-26-082523
SEC filingBruker's revenue grew 2.1% but GAAP operating income fell 73.1% due to tariffs, impairments, and restructuring costs.
Bruker Corporation describes itself as a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. The company operates through four reportable segments: BSI BioSpin, BSI CALID, BSI NANO, and BEST, with corporate headquarters in Billerica, Massachusetts.
The BSI BioSpin Segment focuses on magnetic resonance spectroscopy (NMR and EPR), preclinical imaging (MRI, PET, SPECT, CT, MPI), biopharma and applied solutions, services, integrated data solutions, and automation. Its customers are primarily academic and government research facilities, as well as pharmaceutical and biotechnology companies. The BSI CALID Segment comprises mass spectrometry (MALDI-TOF, ESI-TOF, MRMS, ITMS, IMS, GC-MS, DART-MS, LC-MS), microbiology and infection diagnostics (FluoroType, LiquidArray, InGenius, BeGenius), and optics (FT-IR, NIR, Raman, QCL IR). It serves pharmaceutical, biotech, diagnostics, food, environmental, and forensics markets. The BSI NANO Segment includes Bruker AXS (XRD, XRF, SC-XRD, μCT, EDS, EBSD, S-OES, CS/ONH, STEM), Nano Surfaces and Metrology (AFM, SOM, tribology, NanoIR, Alicona), Spatial Biology (CosMx, GeoMx, nCounter, PaintScape), Fluorescence Microscopy, and Cellular Analysis (Beacon, IsoLight, Canopy). It serves academic, industrial, nanotechnology, and semiconductor customers. The BEST Segment designs and manufactures superconducting materials (LTS, HTS, RRP® conductor), Cuponal™ copper-clad aluminum, and non-superconducting tools for synchrotrons and beamlines.
Key named platforms include MALDI-TOF, timsTOF (trapped ion mobility mass spectrometry), FluoroType and LiquidArray PCR technologies, InGenius and BeGenius sample-to-answer systems, CosMx Spatial Molecular Imager, GeoMx Digital Spatial Profiler, nCounter Analysis System, and PaintScape Spatial 3D Genome platform. The company also offers automation and software solutions for digital transformation and FAIR data principles.
Bruker maintains direct sales forces in North America, Europe, China, Japan, Asia Pacific, Africa, and South America, supplemented by indirect channels such as distributors and independent sales representatives in regions without direct coverage. The sales cycle varies: three to twenty-four months for academic and high-end research products, two weeks to six months for industrial products, and over one year for high-end NMR and superconducting devices. Customer concentration is low, with no single customer exceeding 10% of revenue in the last three fiscal years. Backlog as of December 31, 2025, was approximately $2,569.4 million.
Competition is described as highly competitive with consolidation trends. Key competitors by segment: BSI BioSpin faces JEOL, QOne, Oxford Instruments, and others; BSI CALID competes with Danaher, Agilent, Thermo Fisher Scientific, Biomerieux, and others; BSI NANO competes with Rigaku, Oxford Instruments, Agilent, Zeiss, 10x Genomics, and others; BEST competes with Western Superconducting Technologies, Luvata, Jastec, and others. Competitive factors include technology, applications expertise, product specifications, reliability, marketing, distribution, patents, and cost effectiveness.
Strategic pillars include expanding into high-potential markets, leveraging core strengths, driving recurring revenue through aftermarket and connected services, and committing substantial resources to internal and collaborative R&D (exceeding industry average). The company also pursues acquisitions and minority investments to enhance capabilities and enter new markets, as evidenced by recent acquisitions of Recipe and AST Revolution in the CALID segment.
As of December 31, 2025, Bruker employed approximately 11,085 people worldwide, with 20.2% in the United States. Workforce distribution: 45.8% in production and distribution, 23.5% in selling and marketing, 17.6% in research and development, and 13.1% in general and administrative functions. Bruker emphasizes talent development through performance management, leadership training, employee engagement initiatives, and health and safety programs.
For the fiscal year ended December 31, 2025, Bruker Corporation reported GAAP revenue of $3,436.5 million, a 2.1% increase from $3,366.4 million in 2024. This top-line growth was driven by a 10.4% increase in service and other revenue and a 0.3% increase in product revenue. However, GAAP gross profit declined 4.4% to $1,577.7 million, and GAAP gross margin contracted significantly from 49.0% to 45.9%, a decline of 310 basis points. The margin compression was attributed to higher U.S. tariffs, foreign exchange headwinds from a declining U.S. dollar, unfavorable revenue mix, and increased restructuring costs and impairment charges. GAAP operating income plummeted 73.1% to $68.2 million, resulting in an operating margin of just 2.0% versus 7.5% in the prior year. The decline was primarily driven by a goodwill impairment charge of $96.5 million, higher restructuring costs, and the impact of tariffs and foreign exchange. Net income attributable to Bruker Corporation swung to a loss of $8.6 million from income of $113.1 million in 2024. Non-GAAP metrics also deteriorated: Non-GAAP gross profit margin fell from 51.6% to 49.8%, and Non-GAAP operating margin contracted from 15.4% to 12.6%. Non-GAAP organic revenue declined 3.7% year-over-year, underscoring organic headwinds despite acquisition contributions.
Segment performance was mixed. The BSI CALID segment was the primary growth engine, with revenue increasing 10.7% to $1,210.2 million, driven by higher volumes in the Optics, Microbiology & Infection Diagnostics divisions, and the ELITechGroup molecular diagnostics business acquired in Q2 2024. BSI BioSpin revenue declined 3.0% to $878.8 million, due to fewer GHz-class NMR system sales (two in 2025 vs. four in 2024) and weaker biopharma demand, partially offset by stronger lab automation products. BSI NANO revenue fell 1.3% to $1,084.3 million, hampered by weaker demand in industrial and semiconductor markets and softer academic/government research spending. NanoString, acquired in Q2 2024, partially offset the decline. The BSI NANO segment reported an operating loss of $71.8 million (margin -6.6%) compared to operating income of $2.3 million (margin 0.2%) in the prior year, largely due to a $96.5 million goodwill impairment charge. The BEST segment revenue dropped 4.3% to $270.9 million, driven by softness in the clinical MRI market and a tough prior-year comparison for Research Instruments. Corporate costs not allocated to segments were $137.0 million, up from $121.9 million, primarily from acquisitions and foreign exchange.
Management acknowledged that tariff increases adopted in 2025 and associated global uncertainty have resulted in lower bookings, revenues, and profitability, which may continue. In response, the company announced a cost savings initiative in August 2025 targeting $100 million to $120 million in annualized cost reductions by the end of 2026, affecting supply chain, manufacturing, commercial operations, administration, and R&D. The company also completed a significant debt reduction in 2025, using proceeds from the issuance of Series A Mandatory Convertible Preferred Stock to repay over $593 million in debt. Capital expenditures in 2026 are expected to be consistent with 2025 levels. No formal revenue or earnings guidance was provided, but management expects interest expense to decrease in 2026 due to lower debt levels. The company remains focused on integrating recent acquisitions rather than pursuing new large-scale deals.
As of December 31, 2025, Bruker held $298.8M in cash and cash equivalents. Total debt, comprising $1,852.5M in long-term debt and $16.6M in current maturities, was $1,869.1M. Shareholders' equity increased to $2,473.5M, driven by the issuance of Series A Mandatory Convertible Preferred Stock (net $669.7M) and retained earnings. Inventory increased slightly to $1,094.6M. Deferred revenue (current and long-term) was $550.4M, reflecting customer advances and extended warranty contracts.
The Notes do not disclose any material purchase commitments or contractual obligations beyond standard warranty accruals and lease liabilities. Contingent consideration related to acquisitions is recorded at fair value ($13.4M initially in 2024, but no aggregate commitment figure is provided). Operating lease liabilities total $138.6M current and long-term. No supply or capacity purchase commitments are reported.
In 2025, Bruker repurchased $10.0M of common stock (0.2M shares). Common dividends totaled $30.5M; preferred dividends on the Series A Mandatory Convertible Preferred Stock were $13.9M. Debt management included $466.5M in long-term debt repayments and $778.8M in revolving credit repayments, partially offset by $750.5M in revolver proceeds and $3.5M in new debt, resulting in a net debt reduction of $491.3M. Capital expenditures were $90.8M, or 2.6% of total revenue, primarily for property, plant, and equipment.
The Notes describe four reportable segments (BSI BioSpin, BSI CALID, BSI NANO, BEST) but do not provide segment-level revenue or operating income. Therefore, no segment economics are available from this section. The only segment-specific financial data is the goodwill impairment: BSI NANO (BSB) $54.0M and BSI BioSpin (AUT) $42.5M, totaling $96.5M.
The most significant risk factors in this filing relate to US trade policy and government funding. New US tariffs and reciprocal tariffs imposed in 2025 have already had a material adverse effect on bookings, revenues, and gross margins. The Supreme Court's February 2026 ruling striking down certain IEEPA tariffs adds further uncertainty. Reduced US academic and government funding (NIH, NSF, DOE) has materially adversely affected US academic customer purchases, and this is expected to continue. Delayed release of Chinese government stimulus spending has negatively affected sales growth into China, with China revenue remaining flat year-over-year. Geopolitical tensions (Ukraine, Middle East, US-China) and global economic conditions create ongoing uncertainty.
Supply chain disruptions, including component shortages (especially microelectronic components), continue to cause significant additional costs and manufacturing inefficiencies. The company relies on a limited number of suppliers and contract manufacturers, and supply shortages of raw materials (copper, helium) could adversely affect gross profits. Disruptions at single-location manufacturing facilities could harm customer relationships and revenue.
The company faces substantial competition and rapid technological change that could render its products obsolete. Failure to develop and introduce new products in a timely manner could harm business results. The company's CBRNE detection products face additional risks from lengthy government contracts and stringent acceptance criteria.
Foreign currency exchange rate fluctuations, particularly the strengthening of the Swiss Franc and Euro against the US Dollar, pose a significant risk. Goodwill and intangible asset impairment losses were recorded in 2025. The company has approximately $1.9 billion in debt, and failure to comply with financial covenants could accelerate repayment. Changes in effective income tax rates, including the impact of the One Big Beautiful Bill Act and OECD Pillar Two, could adversely affect results.
Cybersecurity and information technology failures could impact operations, damage reputation, and expose the company to liability. The loss of key personnel or inability to attract talent could affect growth. The company's decentralized operating model presents risks related to resource allocation and integration of acquisitions. Product liability claims, environmental regulations, and failure to maintain effective internal controls are also noted as material risks.
The provided document excerpt does not contain the actual Consolidated Statements of Cash Flows. The text includes only the independent auditor's report and table of contents references. As a result, no cash flow data points (CFO, capex, FCF, share repurchases, dividends) are available for analysis. Without explicit figures, an evaluation of cash flow quality, working capital trends, or capital returns cannot be performed. Future analysis requires the complete cash flow statement section from the 10-K.